Nermin DİNDAR BADEM, Seydi Ali PEKER, Sedat KAYGUSUZ

EŞ ZAMANLI PCT VE CRP İSTENEN TOPLUM KÖKENLİ PNÖMONİ VE KOAH ALEVLENMESİ OLAN HASTALARDA BU PARAMETRELERİN KORELASYONU VE MALİYET ETKİLİLİK AÇISINDAN DEĞERLENDİRİLMES

Amaç: Bakteriyel enfeksiyonlar önemli morbidite ve mortalite nedenidir. Serum prokalsitonin ve C-reaktif protein sistemik inflamasyon ve bakteriyel enfeksiyonların tanı, tedavi ve takibinde önemli belirteçlerdir. Bu çalışmada nihai tanıları pnömoni ve/veya KOAH alevlenmesi olan hastalarda son zamanlarda enfeksiyon takibinde sıklıkla kullanılmaya başlanan prokalsitonin ile klasik belirteç olarak kullanılan C-reaktif protein düzeyleri arasındaki korelasyon araştırıldı. Ayrıca alt solunum yolu enfeksiyonu tanısı ya da yönetimi için C-reaktif proteinin mi, prokalsitoninin mi maliyet etkililik açısından yararlı olduğunu saptamayı amaçladık. Gereç ve Yöntemler: Toplam 1948 hastadan elde edilmiş 4712 örnekten eş zamanlı çalışılan prokalsitonin ve Creaktif protein sonuçları değerlendirildi. Örneklerden 499’u (%10.6) KOAH alevlenmesi (Grup I), 1480’i (%31.4) pnömoni (Grup II) ve 2733 (%58)’i KOAH alevlenmesi ve pnömoni (Grup III) tanısı almış hastaların örneklerinden oluşuyordu. Bulgular: C-reaktif protein ve prokalsitonin düzeyleri arasında pozitif güçlü korelasyon saptandı (rho=0.512, p

Correlation and Assessment of Cost-Effectivity of Simultaneous PCT and CRP Measurements for Patients with Community-Acquired Pneumonia and COPD Inflamation

Objective: Bacterial infections are important causes of morbidity and mortality. Serum procalcitonin and C-reactive protein are significant indicators during the diagnosis, treatment and follow-up of systemic inflammations and bacterial infections. In this study, correlation between levels of procalcitonin, which has recently become commonly used in infection cases, and C-reactive protein, the conventional indicator, were investigated for patients whose final diagnoses were found as pneumonia and/or COPD inflammation. Additionally, the study aimed to determine which among the two indicators was cost-effective for the diagnosis and management of lower respiratory infections. Material and Methods: Procalcitonin and C-reactive protein results of 4712 samples, which were gathered from 1948 patients and measured simultaneously were assessed. Among the samples, 499 (10.6%) were from COPD inflammation patients (Group I), 1480 (31.4%) were from pneumonia patients (Group II), and the remaining 2733 (58%) were from COPD inflammation and pneumonia patients (Group III). Results: A strong positive correlation was detected between Creactive protein and procalcitonin levels (rho=0.512, p

PDF

___

1. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206-17.
2. Çolak A, Yılmaz C, Toprak B, Aktoğu S. Procalcitonin and CRP as biomarkers in discrimination of community-acquired pneumonia and exacerbation of COPD. J Med Biochem. 2017;36(2):122-26. Doi:10.1515/jomb-2017-0011.
3. Taşçı C, Deniz Ö, Tozkoparan E, Özkan M, Balkan A, Bilgiç H ve ark. Toplum kökenli pnömonilerde serum prokalsitonin değerleri ile diğer akut faz reaktanları ve hastalığın radyolojik yaygınlığı arasındaki ilişki. Toraks Dergisi. 2007;8(3):156-62.
4. Taşbakan MS, Gündüz C, Sayıner A, Çilli A, Çelenk Karaboğa B, Şakar Çoşkun A et al. Serum procalcitonin and C-reactive protein kinetics as indicators of treatment outcome in hospitalized patients with community-acquired pneumonia. Turk J Med Sci. 2016;46(5):1422-7. Doi:10.3906/sag1507-20.
5. Müller F, Christ-Crain, Bregenzer T, Krause M, Zimmerli W, Mueller B et al. Procalcitonin levels predict bacteremia in patients with communityacquired pneumonia. Chest. 2010;138(1):121-9. Doi:10.1378/chest.09-2920.
6. Özlü T, Bülbül Y, Alataş F, Arseven O, Şakar Coşkun A, Çilli A ve ark. Türk Toraks Derneği erişkinlerde toplumda gelişen pnömoni tanı ve tedavi uzlaşı raporu. Türk Toraks Dergisi. 2009;10(Supp 9):1-16.
7. Lacoma A, Prat C, Andreo F, Lores L, RuizManzano J, Ausina V et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. International Journal of COPD. 2011;6:157-69. Doi:10.2147/COPD.S16070.
8. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax. 2006;61(3):250-8.
9. Akcay I, Okoh AK, Yalav O, Eray IC, Rencuzogullari A, Dalci K et al. The prognostic value of pro-calcitonin, CRP and thyroid hormones in secondary peritonitis: a single-center prospective study. Ulus Travma Acil Cerrahi Derg. 2014;5(20):343-52.
10.Christ-Crain M, Opal SM. Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Critical Care. 2010;203(14):1-11.
11. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial ınfection and sepsis? Infect Control Hosp Epidemiol. 2015;36(3):265-72.
12. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Medicine. 2019;7:2050312119835043. Doi:10.1177/2050312119835043.
13. Price CP, Trull AK, Berry D, Gorman EG. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J Immunol Methods. 1987;99(2):205-11
14. Meisner M. Procalcitonin (PCT)-A new innovative infection parameter. Biochemical and clinical aspects. In: Meisner M, ed. Procalcitonin (PCT)-A New, Innovative Infection Parameter. Biochemical and Clinical Aspects. 3rd ed. New York. Thieme Publishers, 2000:63-8.
15. Yoon YK, Kim MJ, Yang KS, Ham SY. The role of serum procalcitonin in the differential diagnosis of pneumonia from pulmonary edema among the patients with pulmonary infiltrates on chest radiography. Medicine. 2018;97(47):1-7. Doi:10.1097/MD.0000000000013348.
16. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: Clinical Evidence and Perspectives. Eur J Intern Med. 2011;22(5):460-5.
17. Micaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitoninguided antibiotic therapy for outpatient management of acute respiratory tract ınfections in adults. J Gen Intern Med. 2013;29(4):579-86. Doi:10.1007/s11606-013-2679-7.
18.Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-74. Doi:10.1016/S0140-6736(09)61879-1.
19. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007;7:102.
20. Drozdov D, Dusemund F, Müller B, Werner, Albrich C. Efficacy and safety of procalcitoninguided antibiotic therapy in lower respiratory tract ınfections. Antibiotics. 2013,2(1):1-10. Doi:10.3390/antibiotics2010001.
21. Poyrazoğlu MH, Per H, Öztürk M, Bingöl N, Üzüm K. Çocukluk çağı pnömonilerinde serum prokalsitonin düzeyleri. Çocuk Sağlığı ve Hastalıkları Dergisi. 2002;46(3):169-76.
22. Does Y, Limper M, Schuit SCE, Poley MJ, Rosmalen J, Ramakers C et al. Higher diagnostic accuracy and costeffectiveness using procalcitonin in the treatment of emergency medicine patients with fever (The HiTEMP study): a multicenter randomized study. BMC Emergency Medicine. 2016;16(17):1-7. Doi:10.1186/s12873-016-0081-6.
23.Bafadhel M, Clark TW, Reid C, Medina M, Batham S, Barer MR. Procalcitonin and C-reactive protein in hospitalized adult patients with communityacquired pneumonia or exacerbation of asthma or COPD. CHEST. 2011;139(6):1410-8. Doi:10.1378/chest.10-1747.